Welcome to CME Academy:
CME Credits for Academy Chapters
At Psychiatry Education Forum, we understand the importance of continuous learning and professional development in the ever-evolving field of psychiatry. That’s why we are excited to introduce CME Academy, an exclusive feature designed for our medical professionals who wish to enhance their knowledge and claim Continuing Medical Education (CME) credits for an afforadable pricing.
Whether you’re a busy clinician, an early-career psychiatrist, or a resident looking to enhance your knowledge, CME Academy offers an accessible way to stay updated on clinically relevant psychiatry topics while earning Continuing Medical Education credits.
What is CME Academy?
CME Academy is your gateway to advanced, high-quality educational content tailored specifically for medical professionals. Through CME Academy, you can purchase individual courses that are accredited for CME credits.
We’ve carefully selected topics that are of direct relevance to your daily clinical practice, ensuring that what you learn can be immediately applied to improve patient care.
All courses available through CME Academy are accredited and recognized, ensuring that these courses help you maintain your licensing requirements with ease, ensuring you're always up to date with the latest in psychiatry.
All our courses are free from pharmaceutical or non-pharmaceutical influence, ensuring that the education you receive is unbiased and focused purely on enhancing your clinical practice.
Access CME credits at a competitive rate. Purchase only the courses that are relevant to your practice and interests, without committing to an entire bundle.
CME ACADEMY:
TABLE OF CONTENT
(CME 1) Mastering Major Depressive Disorder Psychopharmacology
ENROLLMENT CLOSED
- Total Credits: 8.50 AMA PRA Category 1 Credits.
- CME EXPIRED on: September 1, 2025.
Learning Objectives:
- Evaluate the pharmacological mechanisms and clinical efficacy of various antidepressants used in treating Major Depressive Disorder.
- Apply evidence-based strategies to optimize antidepressant selection and dosing, tailored to individual patient profiles.
- Integrate adjunctive treatment options to enhance therapeutic outcomes in patients with treatment-resistant depression.
- Differentiate between various antidepressants in terms of their pharmacokinetics, efficacy, and side effect profiles.
(CME 2) Guide to Understanding & Managing Schizophrenia
ENROLLMENT CLOSED
- Total Credits: 7.75 AMA PRA Category 1 Credits.
- CME Expiring on: September 28, 2025.
Learning Objectives:
- Compare and evaluate the efficacy, dosing, and side effects of 32 antipsychotics in the treatment of acute multi-episode schizophrenia.
- Implement evidence-based strategies for the management of clozapine-resistant schizophrenia and develop protocols for managing missed doses of clozapine.
- Assess and mitigate the risks associated with antipsychotic use, particularly the risk of pneumonia.
- Differentiate the effectiveness of various antipsychotic formulations, including Aripiprazole versus Brexpiprazole and topical versus sublingual Asenapine.
- Integrate psychological interventions for treating auditory hallucinations alongside pharmacological therapies.
- Understand the impact of schizophrenia’s progression with age on long-term management strategies.
- Recognize the implications of adolescent cannabis use on the risk of developing schizophrenia.
- Stay updated on the latest research regarding the glutamatergic synapse in schizophrenia.
(CME 3) Comprehensive Approaches for Managing Adverse Events with Psychopharmacology
ENROLLMENT CLOSING ON: OCT 13, 2025
- Total Credits: 6.75 AMA PRA Category 1 Credits.
- CME Expiring on: October 26, 2025.
Learning Objectives:
- Identify and manage common adverse effects associated with antipsychotics, Mood Stabilizers and Antidepressants.
- Develop targeted treatment plans for specific adverse events of antipsychotics like Clozapine and Mood Stabilizers like Lithium.
- Evaluate the comparative efficacy of VMAT-2 inhibitors for tardive dyskinesia management to optimize patient outcomes.
- Assess the relationship between antipsychotic use and breast cancer risk to guide safer long-term treatment planning.
- Recognize and address antidepressant-induced adverse effects, such as bruxism, excessive sweating, and other condition-specific risks, to improve patient comfort and adherence to treatment.